相対的治療効果および絶対的アウトカムに関するモデルに基づくメタ解析 （MBMA） ： 概念と応用を中心に
2025年5月27日 - 11:00 東部標準時間（ET）
Danielle Pillsbury2025年4月10日
Model-Based Meta-Analysis for All Phases of Drug Development: Capturing the Full Potential of Published Clinical Trial Outcomes [APAC Webinar]
2025年5月29日 - 10am Japan/Korea, 9am in China
Danielle Pillsbury2025年4月3日
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)
In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…
Danielle Pillsbury2025年1月9日
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease
The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…
Danielle Pillsbury2025年1月8日
Using MBMA to run virtual “head-to-head trials”
Osteoporosis is common in post-menopausal women. The long-term sequelae of osteoporosis include bone fractures, particularly…
Danielle Pillsbury2023年4月21日
A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease
New therapeutics discovery and development for ocular diseases have been traditionally associated with a low…
Certara2021年12月15日
Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development
Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…
Certara2019年12月19日
Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond
Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly…
Jieun Choe2018年6月2日
